- Home
- OPHC vs RVPH Comparison
OPHC vs RVPH Comparison
Compare OPHC & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- RVPH
- Stock Information
- Founded
- OPHC 2000
- RVPH 2006
- Country
- OPHC United States
- RVPH United States
- Employees
- OPHC N/A
- RVPH N/A
- Industry
- OPHC Major Banks
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- OPHC Finance
- RVPH Health Care
- Exchange
- OPHC Nasdaq
- RVPH Nasdaq
- Market Cap
- OPHC 43.1M
- RVPH 36.7M
- IPO Year
- OPHC N/A
- RVPH N/A
- Fundamental
- Price
- OPHC $4.37
- RVPH $0.70
- Analyst Decision
- OPHC
- RVPH Strong Buy
- Analyst Count
- OPHC 0
- RVPH 5
- Target Price
- OPHC N/A
- RVPH $9.00
- AVG Volume (30 Days)
- OPHC 9.1K
- RVPH 656.2K
- Earning Date
- OPHC 08-05-2025
- RVPH 08-13-2025
- Dividend Yield
- OPHC N/A
- RVPH N/A
- EPS Growth
- OPHC 30.24
- RVPH N/A
- EPS
- OPHC 1.33
- RVPH N/A
- Revenue
- OPHC $39,980,000.00
- RVPH N/A
- Revenue This Year
- OPHC N/A
- RVPH N/A
- Revenue Next Year
- OPHC N/A
- RVPH N/A
- P/E Ratio
- OPHC $3.30
- RVPH N/A
- Revenue Growth
- OPHC 53.28
- RVPH N/A
- 52 Week Low
- OPHC $3.53
- RVPH $0.49
- 52 Week High
- OPHC $5.90
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- OPHC 48.76
- RVPH 39.46
- Support Level
- OPHC $4.36
- RVPH $0.67
- Resistance Level
- OPHC $4.62
- RVPH $0.90
- Average True Range (ATR)
- OPHC 0.07
- RVPH 0.06
- MACD
- OPHC -0.01
- RVPH -0.02
- Stochastic Oscillator
- OPHC 32.90
- RVPH 11.36
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides a range of community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal account, money market deposit accounts, debit cards, and automated teller machines.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.